<DOC>
	<DOCNO>NCT00916370</DOCNO>
	<brief_summary>To evaluate safety effectiveness XIENCE PRIME XIENCE PRIME Long Lesion ( LL ) Everolimus Eluting Coronary Stent System ( EECSS ) improve coronary luminal diameter subject symptomatic heart disease due maximum two de novo native coronary artery lesion , different epicardial vessel .</brief_summary>
	<brief_title>SPIRIT PRIME Clinical Trial</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Coronary Stenosis</mesh_term>
	<mesh_term>Coronary Restenosis</mesh_term>
	<criteria>1 . Subject must least 18 year age . 2 . Subject legally authorize representative must provide write informed consent prior study related procedure , per site requirement . 3 . Subject must evidence myocardial ischemia ( e.g. , stable unstable angina , silent ischemia , positive functional study reversible change electrocardiogram ( ECG ) consistent ischemia ) . 4 . Subject must acceptable candidate coronary artery bypass graft ( CABG ) surgery . 5 . Subject must agree undergo protocolrequired followup procedure . 6 . Subject must agree participate clinical study period one year follow index procedure . Angiographic Inclusion Criteria 1 . One two de novo target lesion different epicardial vessel . 2 . If two target lesion , lesion must satisfy angiographic eligibility criterion registry . Multiple focal de novo lesion target vessel cover single stent allow . 3 . The target lesion ( ) must locate major artery branch visually estimate diameter stenosis ≥ 50 % &lt; 100 % TIMI flow ≥ 1 . 4 . Target lesion ( ) must locate native coronary artery reference vessel diameter ( RVD ) visual estimation : ≥ 2.25 mm ≤ 4.25 mm treatment core size XIENCE PRIME EECS ≥ 2.5 mm ≤ 4.25 mm treatment XIENCE PRIME LL EECS 5 . Target lesion ( ) must locate native coronary artery length visual estimation : ≤ 22 mm treatment core size XIENCE PRIME EECS &gt; 22 mm ≤ 32 mm treatment XIENCE PRIME LL EECS 1 . Subject know diagnosis acute myocardial infarction ( AMI ) precede index procedure ( CKMB ≥ 2 time upper limit normal ) CK CKMB return within normal limit time procedure . 2 . The subject currently experience clinical symptom consistent new onset AMI , nitrateunresponsive prolong chest pain ischemic ECG change . 3 . Subject current unstable cardiac arrhythmia associate hemodynamic instability . 4 . Subject know leave ventricular ejection fraction ( LVEF ) &lt; 30 % ( LVEF may obtain time index procedure value unknown necessary ) . 5 . Subject receive coronary brachytherapy epicardial vessel ( target non target ) . 6 . Subject receive organ transplant wait list organ transplant . 7 . Subject receive schedule receive chemotherapy malignancy within 30 day prior within one year index procedure . 8 . Subject receive schedule receive plan radiotherapy chest/mediastinum . 9 . Subject receive immunosuppressant therapy know immunosuppressive autoimmune disease ( e.g . human immunodeficiency virus , systemic lupus erythematosus etc. ) . 10 . Subject receive chronic anticoagulation therapy ( e.g. , heparin , coumadin ) . 11 . Subject require Low Molecular Weight Heparin ( LMWH ) postprocedure . 12 . Subject know hypersensitivity contraindication aspirin , heparin/bivalirudin , clopidogrel/ticlopidine , everolimus , cobalt , chromium , nickel , tungsten , acrylic fluoro polymer contrast sensitivity adequately premedicated . 13 . Elective surgery plan within 12 month procedure require discontinue either aspirin clopidogrel . 14 . Subject platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 , white blood cell ( WBC ) &lt; 3,000 cells/mm3 , document suspect liver disease ( include laboratory evidence hepatitis ) . 15 . Subject know renal insufficiency ( example limit estimate glomerular filtration rate ( eGFR ) &lt; 60 ml/kg/m2 , serum creatinine level ≥ 2.5 mg/dL , dialysis ) . 16 . Subject history bleed diathesis coagulopathy refuse blood transfusion . 17 . Subject cerebrovascular accident/stroke transient ischemic neurological attack ( TIA ) within past six month . 18 . Subject significant gastrointestinal significant urinary bleed within past six month . 19 . Subject extensive peripheral vascular disease precludes safe 6 French sheath insertion . 20 . Subject medical illness ( e.g. , cancer congestive heart failure ) know history substance abuse ( alcohol , cocaine , heroin etc . ) may cause noncompliance protocol , confound data interpretation associate limited life expectancy ( i.e. , less one year ) . 21 . Subject currently participate another clinical study yet complete primary endpoint . 22 . Pregnant nursing subject plan pregnancy period 1 year follow index procedure . Female subject childbearing potential must negative pregnancy test do within 7 day prior index procedure per site standard test . Angiographic Exclusion Criteria All angiographic exclusion criterion base visual estimation . 1 . Target lesion locate within arterial saphenous vein graft distal diseased ( vessel irregularity per angiogram &gt; 20 % stenosed lesion ) arterial saphenous vein graft . 2 . Target lesion involve bifurcation side branch ≥ 2 mm diameter and/or ostial lesion &gt; 40 % stenosed side branch require protection guide wire , side branch require dilatation . 3 . Target lesion total occlusion ( TIMI flow 0 ) , prior cross wire . 4 . Another lesion require revascularization locate epicardial vessel target lesion . 5 . Restenotic target lesion . 6 . Aortoostial target lesion ( within 3 mm aorta junction ) . 7 . Target lesion leave main location . 8 . Target lesion locate within 2 mm origin LAD LCX . 9 . Extreme angulation ( ≥ 90 ° ) excessive tortuosity ( ≥ two 45° angle ) proximal within lesion . 10 . Heavy calcification proximal within target lesion . 11 . Target vessel contains thrombus indicate angiographic image . 12 . Target lesion high probability procedure predilatation stenting require time index procedure treatment target vessel ( e.g . atherectomy , cut balloon ) . 13 . Target vessel previously treat type PCI ( e.g . balloon angioplasty , stent , cut balloon , atherectomy ) &lt; 9 month prior index procedure . 14 . Nontarget vessel previously treat type PCI &lt; 90 day prior index procedure . 15 . Additional clinically significant lesion ( ) ( e.g . % DS ≥ 50 % ) target vessel side branch PCI may require &lt; 90 day index procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>drug elute stent</keyword>
	<keyword>stent</keyword>
	<keyword>Angioplasty</keyword>
	<keyword>myocardial ischemia</keyword>
	<keyword>coronary artery stenosis</keyword>
	<keyword>Coronary Disease</keyword>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Coronary Restenosis</keyword>
	<keyword>Long lesion</keyword>
</DOC>